REGULUS THERAPEUTICS INC (RGLS) Fundamental Analysis & Valuation

NASDAQ:RGLS • US75915K3095

8.16 USD
+0.02 (+0.25%)
At close: Jun 24, 2025
8.02 USD
-0.14 (-1.72%)
After Hours: 6/24/2025, 8:00:02 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This RGLS fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

3

Taking everything into account, RGLS scores 3 out of 10 in our fundamental rating. RGLS was compared to 519 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for RGLS as it has an excellent financial health rating, but there are worries on the profitability. RGLS is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

0

1. RGLS Profitability Analysis

1.1 Basic Checks

  • RGLS had negative earnings in the past year.
  • In the past year RGLS has reported a negative cash flow from operations.
  • In the past 5 years RGLS always reported negative net income.
  • In the past 5 years RGLS always reported negative operating cash flow.
RGLS Yearly Net Income VS EBIT VS OCF VS FCFRGLS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -63.51%, RGLS is doing worse than 61.22% of the companies in the same industry.
  • With a Return On Equity value of -68.85%, RGLS perfoms like the industry average, outperforming 55.83% of the companies in the same industry.
Industry RankSector Rank
ROA -63.51%
ROE -68.85%
ROIC N/A
ROA(3y)-71.13%
ROA(5y)-59.17%
ROE(3y)-95.84%
ROE(5y)-79.71%
ROIC(3y)N/A
ROIC(5y)N/A
RGLS Yearly ROA, ROE, ROICRGLS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K

1.3 Margins

  • RGLS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
RGLS Yearly Profit, Operating, Gross MarginsRGLS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20K -40K -60K -80K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. RGLS Health Analysis

2.1 Basic Checks

  • RGLS has more shares outstanding than it did 1 year ago.
  • RGLS has more shares outstanding than it did 5 years ago.
  • RGLS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
RGLS Yearly Shares OutstandingRGLS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
RGLS Yearly Total Debt VS Total AssetsRGLS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

  • An Altman-Z score of 46.61 indicates that RGLS is not in any danger for bankruptcy at the moment.
  • RGLS's Altman-Z score of 46.61 is amongst the best of the industry. RGLS outperforms 98.03% of its industry peers.
  • RGLS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 46.61
ROIC/WACCN/A
WACCN/A
RGLS Yearly LT Debt VS Equity VS FCFRGLS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M 60M

2.3 Liquidity

  • RGLS has a Current Ratio of 16.31. This indicates that RGLS is financially healthy and has no problem in meeting its short term obligations.
  • RGLS's Current ratio of 16.31 is amongst the best of the industry. RGLS outperforms 89.59% of its industry peers.
  • A Quick Ratio of 16.31 indicates that RGLS has no problem at all paying its short term obligations.
  • Looking at the Quick ratio, with a value of 16.31, RGLS belongs to the top of the industry, outperforming 89.59% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 16.31
Quick Ratio 16.31
RGLS Yearly Current Assets VS Current LiabilitesRGLS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. RGLS Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 50.00% over the past year.
EPS 1Y (TTM)50%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%48.28%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, RGLS will show a very strong growth in Earnings Per Share. The EPS will grow by 47.01% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-5.52%
EPS Next 2Y-11.37%
EPS Next 3Y22.97%
EPS Next 5Y47.01%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
RGLS Yearly Revenue VS EstimatesRGLS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2027 2028 2029 2030 2031 200M 400M 600M 800M 1B
RGLS Yearly EPS VS EstimatesRGLS Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -50 -100 -150

More info and screens

Find the best growth stocksShow best growing peers

1

4. RGLS Valuation Analysis

4.1 Price/Earnings Ratio

  • RGLS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for RGLS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RGLS Price Earnings VS Forward Price EarningsRGLS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RGLS Per share dataRGLS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1

4.3 Compensation for Growth

  • A more expensive valuation may be justified as RGLS's earnings are expected to grow with 22.97% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-11.37%
EPS Next 3Y22.97%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. RGLS Dividend Analysis

5.1 Amount

  • RGLS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

RGLS Fundamentals: All Metrics, Ratios and Statistics

REGULUS THERAPEUTICS INC

NASDAQ:RGLS (6/24/2025, 8:00:02 PM)

After market: 8.02 -0.14 (-1.72%)

8.16

+0.02 (+0.25%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-08
Earnings (Next)08-06
Inst Owners82.87%
Inst Owner Change0%
Ins Owners2.8%
Ins Owner Change0%
Market Cap564.92M
Revenue(TTM)N/A
Net Income(TTM)-47.52M
Analysts73.33
Price Target8.67 (6.25%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)23.3%
Min EPS beat(2)6.63%
Max EPS beat(2)39.98%
EPS beat(4)2
Avg EPS beat(4)2.97%
Min EPS beat(4)-21.11%
Max EPS beat(4)39.98%
EPS beat(8)5
Avg EPS beat(8)-0.32%
EPS beat(12)7
Avg EPS beat(12)2.1%
EPS beat(16)9
Avg EPS beat(16)0.36%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-3.41%
PT rev (3m)-27.97%
EPS NQ rev (1m)1.85%
EPS NQ rev (3m)12.4%
EPS NY rev (1m)23.3%
EPS NY rev (3m)11.59%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 8.18
P/tB 8.19
EV/EBITDA N/A
EPS(TTM)-0.73
EYN/A
EPS(NY)-1.08
Fwd EYN/A
FCF(TTM)-0.63
FCFYN/A
OCF(TTM)-0.63
OCFYN/A
SpS0
BVpS1
TBVpS1
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -63.51%
ROE -68.85%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-71.13%
ROA(5y)-59.17%
ROE(3y)-95.84%
ROE(5y)-79.71%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 31.62%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 16.31
Quick Ratio 16.31
Altman-Z 46.61
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)221.31%
Cap/Depr(5y)143.72%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)50%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%48.28%
EPS Next Y-5.52%
EPS Next 2Y-11.37%
EPS Next 3Y22.97%
EPS Next 5Y47.01%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-58.92%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-22%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-58.64%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-59.74%
OCF growth 3YN/A
OCF growth 5YN/A

REGULUS THERAPEUTICS INC / RGLS FAQ

Can you provide the ChartMill fundamental rating for REGULUS THERAPEUTICS INC?

ChartMill assigns a fundamental rating of 3 / 10 to RGLS.


What is the valuation status for RGLS stock?

ChartMill assigns a valuation rating of 1 / 10 to REGULUS THERAPEUTICS INC (RGLS). This can be considered as Overvalued.


How profitable is REGULUS THERAPEUTICS INC (RGLS) stock?

REGULUS THERAPEUTICS INC (RGLS) has a profitability rating of 0 / 10.